Comparison of Anxiety Levels in MDR-TB Patients with Individual and Short-term Regimens at Dr. Soebandi Regional General Hospital, Jember, Indonesia
Downloads
Introduction: Multidrug-resistant tuberculosis (MDR-TB) is a form of TB that shows resistance to both isoniazid and rifampicin. Globally, the number of new MRD-TB cases has continued to rise since 2020. Indonesia is positioned among the top ten countries with the highest incidence of MDR-TB worldwide. Specifically, Jember ranked second in the number of MDR-TB cases in East Java. This study aimed to assess the comparison between the administration of individual MDR-TB regimens and short-term regimens concerning anxiety levels in MDR-TB patients at Dr. Soebandi Regional General Hospital, Jember.
Methods: This was an analytical observational study with a cross-sectional design. It was conducted at Dr. Soebandi Regional General Hospital, Jember, using interviews and medical record data from August to September 2023. The sample size was 69 participants, who were obtained through consecutive sampling. Analysis was performed using the Statistical Package for the Social Sciences (SPSS) and the Chi-Square test for group comparisons.
Results: This study found that 64% of subjects received individual regimens. In the individual regimen group, 80% of subjects reported anxiety. Among the short-term regimen group, 60% of subjects showed no anxiety. The significance value of this study was 0.007 in the Chi-Square test for group differences.
Conclusion: There was a difference in anxiety levels between individual and short-term regimens among MDR-TB patients at Dr. Soebandi Regional General Hospital, Jember. Patients with anxiety were more common in individual regimens compared to short-term regimens.
Jang JG, Chung JH. Diagnosis and Treatment of Multidrug-Resistant Tuberculosis. Yeongnam Univ J Med 2020; 4: 277–285. [PubMed]
(WHO) WHO. WHO Consolidated Guidelines on Tuberculosis: Module 4: Treatment: Drug-Susceptible Tuberculosis Treatment. Geneva, https://www.who.int/publications/i/item/9789240048126 (2022).
World Health Organization (WHO). Global Tuberculosis Report 2022. Geneva, https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022 (2022).
Timur BPSPJ. Jumlah Kasus Penyakit Menurut Kabupaten/Kota dan Jenis Penyakit di Provinsi Jawa Timur, 2021. Surabaya, https://jatim.bps.go.id/statictable/2022/11/02/2389/jumlah-kasus-penyakit-menurut-kabupaten-kota-dan-jenis-penyakit-di-provinsi-jawa-timur-2021.html (2022).
Wibowo A, Burhan E, Putra AC. Pola Resistansi Kuman Tuberkulosis dan Regimen Pengobatan pada Pasien Tuberkulosis Resisten Obat di Rumah Sakit Pusat Rujukan Respirasi Nasional Persahabatan Jakarta. J Kedokt Univ Lampung 2021; 5: 1–6. [Journal]
Husna CH Al. Hubungan Lama Menjalani Hemodialisis dengan Kecemasan Pasien. Indones J Nurs Heal 2021; 6: 31–38. [Journal]
Walker IF, Kanal S, Baral SC, et al. Depression and Anxiety in Patients with Multidrug-Resistant Tuberculosis in Nepal: An Observational Study. Public Heal Action 2019; 9: 42–48. [PubMed]
Kempker RR, Smith AGC, Avaliani T, et al. Cycloserine and Linezolid for Tuberculosis Meningitis: Pharmacokinetic Evidence of Potential Usefulness. Clin Infect Dis 2022; 75: 682–689. [PubMed]
Shivekar SS, Kaliaperumal V, Brammacharry U, et al. Prevalence and Factors Associated with Multidrug-Resistant Tuberculosis in South India. Sci Rep 2020; 10: 17552. [Journal]
Saifullah A, Mallhi TH, Khan YH, et al. Evaluation of Risk Factors Associated with the Development of MDR- and XDR-TB in a Tertiary Care Hospital: A Retrospective Cohort Study. PeerJ 2021; 9: e10826. [PubMed]
Cheng Q, Xie L, Wang L, et al. Incidence Density and Predictors of Multidrug-Resistant Tuberculosis Among Individuals with Previous Tuberculosis History: A 15-Year Retrospective Cohort Study. Front Public Heal; 9, https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2021.644347 (2021).
Imam FRS, Umboh JML, Tuda JSB. Faktor-Faktor Risiko yang Berhubungan dengan Kejadian Multidrug-Resistant Tuberculosis (TB-MDR) di Kota Ternate, Maluku Utara. e-CliniC 2023; 11: 260–268. [Journal]
Juliati L, Makhfudli M, Wahyudi AS. Analysis Factors Influence Compliance Behavior of Drug Prevention and Drug Compliance on Tuberculosis Patient Based on Health Belief Model. Indones J Community Heal Nurs 2020; 5: 62–71. [Journal]
Bawonte TG, Mambo CD, Masengi ASR. Faktor-Faktor yang Mempengaruhi Tuberculosis Multidrug Resistance (TB MDR). eBiomedik 2021; 9: 117–125. [Journal]
Nunn AJ, Phillips PPJ, Meredith SK, et al. A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med 2019; 380: 1201–1213. [PubMed]
Espinosa-Pereiro J, Sánchez-Montalvá A, Aznar ML, et al. MDR Tuberculosis Treatment. Medicina (Kaunas); 58. Epub ahead of print January 2022. [PubMed]
Yadav S. Cycloserine-Induced Insomnia and Psychosis in Multidrug-Resistant Pulmonary Tuberculosis - A Case Report. Cureus 2022; 14: e32963. [PubMed]
Farida F. Faktor Keberhasilan Pengobatan Multi Drug Resistance Tuberculosa (MDR-TB) di Indonesia : Tinjauan Sistematik. J Heal Epidemiol Commun Dis; 6. Epub ahead of print 12 November 2020. [Journal]
Otu A, Offor JB, Ekpor IA, et al. New-Onset Psychosis in a Multi-Drug Resistant Tuberculosis Patient on Cycloserine in Calabar, Nigeria: A Case Report. Trop J Pharm Res 2014; 13: 303. [ResearchGate]
Duko B, Bedaso A, Ayano G. The Prevalence of Depression among Patients with Tuberculosis: A Systematic Review and Meta-Analysis. Ann Gen Psychiatry 2020; 19: 30. [PubMed]
Laxmeshwar C, Das M, Mathur T, et al. Psychiatric Comorbidities among Patients with Complex Drug-Resistant Tuberculosis in Mumbai, India. PLoS One 2022; 17: e0263759. [PubMed]
Liu K, Zhang Y, Qu S, et al. Prevalence and Correlates of Anxiety and Depressive Symptoms in Patients with and without Multi-Drug Resistant Pulmonary Tuberculosis in China. Front Psychiatry 2021; 12: 674891. [PubMed]
Srinivasan G, Chaturvedi D, Verma D, et al. Prevalence of Depression and Anxiety among Drug Resistant Tuberculosis: A Study in North India. Indian J Tuberc 2021; 68: 457–463. [PubMed]
Numpong S, Kengganpanich M, Kaewkungwal J, et al. Confronting and Coping with Multidrug-Resistant Tuberculosis: Life Experiences in Thailand. Qual Health Res 2021; 32: 159–167. [PubMed]
Susanto TD, Widysanto A, Cipta DA, et al. Anxiety and Depression Level of Patients with Multidrug-Resistant Tuberculosis (MDR-TB) in Two Hospitals in Banten Province, Indonesia. Dialogues Heal 2023; 2: 100115. [PubMed]
Nahid P, Mase SR, Migliori GB, et al. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med 2019; 200: e93–e142. [PubMed]
Simanjuntak M, Efendy I, Yuniati Y, et al. Factors Affecting the Behavior of Lung-Tb Patients in Preventing Transmission. J Community Heal Provis 2022; 2: 105–115. [Journal]
Azam M, Fibriana A, Indrawati F, et al. Prevalence and Determinant of Depression among Multi-Drug Resistance Tuberculosis: Study in Dr. Kariadi General Hospital. J Respirologi Indones 2020; 40: 88–96. [Journal]
Anye LC, Bissong MEA, Njundah AL, et al. Depression, Anxiety and Medication Adherence among Tuberculosis Patients Attending Treatment Centres in Fako Division, Cameroon: Cross-Sectional Study. BJPsych Open 2023; 9: e65. [PubMed]
Soedarsono S. Tuberculosis: Development of New Drugs and Treatment Regimens. J Respirasi 2021; 7: 36–45. [Journal]
Liu Y, Sun Y, Zhang X, et al. Evaluation of the Frequency of Mutation Genes in Multidrug-Resistant Tuberculosis (MDR-TB) Strains in Beijing, China. Epidemiol Infect 2021; 149: e21. [PubMed]
Copyright (c) 2024 Ida Srisurani Wiji Astuti, Muhammad Rifqy Alvy Widodo, Inke Kusumastuti, Angga Mardro Raharjo, Supangat, Justina Evy Tyaswati, Noor Fadzilah binti Zulkifli
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions.
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
4. The Creative Commons Attribution Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under "the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violation.